Global Thalassemia Treatment Market Size, Share, Forecast Report, 2020-2027

The global Thalassemia Treatment market garnered revenue around USD XX Billion in 2019 and projected to reach USD 3700 Million in 2027, with at a compound annual growth rate of 11% throughout the estimate period from 2020 to 2027.

Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation. Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia.

Market Restraints

• Stringent regulatory policies

• High treatment costs

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Thalassemia Treatment market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Thalassemia Treatment market growth.

The global Thalassemia Treatment market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

Novartis AG (Switzerland)

Bluebird Bio, Inc. (US)

Kiadis Pharma (Netherlands)

CELGENE CORPORATION (US)

Sangamo Therapeutics (US)

Acceleron Pharma, Inc. (US)

Gamida Cell (Israel)

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Type

Alpha-thalassemia

Beta Thalassemia

By Treatment

Blood Transfusions

Iron Chelation Therapy

Folic Acid Supplements

Gene therapy

Bone Marrow transplants

By End-User

Hospitals & Clinics

Diagnostic laboratories

Others

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

• North America

? U.S.

? Canada

• Europe

? Germany

? U.K.

? Italy

? France

? Rest of EU

• Asia Pacific

? China

? India

? Japan

? Southeast Asia

? Rest of APAC

• Central & South America

? Brazil

? Argentina

? Rest of Central & South America

• Middle East and Africa

? UAE

? Saudi Arabia

? Rest of MEA